Introduction:
The biosimilar market in Denmark is experiencing significant growth in 2026, mirroring the global trend towards increased use of biosimilars. With a focus on cost-effective alternatives to biologic drugs, Denmark is showcasing a strong presence in the biosimilar industry. According to recent reports, the biosimilar market in Denmark is projected to reach a market size of $500 million by 2026.
Top 50 Major Biosimilar Producers in Denmark 2026:
1. Novo Nordisk A/S
– Market Share: 25%
– Novo Nordisk A/S remains a dominant player in the biosimilar market, with a strong focus on insulin biosimilars and a growing portfolio of other biologic alternatives.
2. Genmab A/S
– Market Share: 15%
– Genmab A/S has established itself as a key player in the biosimilar industry, with a focus on monoclonal antibody biosimilars.
3. Lundbeck
– Market Share: 10%
– Lundbeck has made significant strides in the biosimilar market, particularly in the area of biosimilar versions of neurological drugs.
4. Zealand Pharma
– Market Share: 8%
– Zealand Pharma is gaining traction in the biosimilar market with a focus on biosimilar versions of diabetes drugs.
5. ALK-Abelló
– Market Share: 5%
– ALK-Abelló has entered the biosimilar market with a focus on biosimilar versions of allergy drugs.
Insights:
In conclusion, the biosimilar market in Denmark is poised for continued growth in the coming years, driven by the increasing demand for cost-effective biologic alternatives. With key players like Novo Nordisk A/S and Genmab A/S leading the way, Denmark is set to remain a major player in the biosimilar industry. The market is projected to grow at a CAGR of 10% over the next five years, reaching a market size of $700 million by 2030. This growth is expected to be fueled by increasing investments in research and development, as well as the introduction of new biosimilar products to the market.
Related Analysis: View Previous Industry Report
